Literature DB >> 3514684

Use of Leu M1 and antiepithelial membrane antigen monoclonal antibodies for diagnosing Hodgkin's disease.

A S Jack, D Cunningham, M Soukop, C N Liddle, F D Lee.   

Abstract

Biopsies of 82 patients diagnosed as having Hodgkin's disease were reviewed. Seventeen were reclassified histologically as non-Hodgkin's lymphoma or reactive lymphoid hyperplasia. A substantial number of cases of Hodgkin's disease were negative when stained with Leu M1. Staining for Leu M1 was not found in the cases of non-Hodgkin's lymphoma or reactive lymphoid hyperplasia. With the exception of the lymphocyte predominant nodular subtype of Hodgkin's disease, epithelial membrane antigen staining was seen in a few cases of Hodgkin's disease and non-Hodgkin's lymphomas. This was not a useful discriminating feature.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3514684      PMCID: PMC499760          DOI: 10.1136/jcp.39.3.267

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  7 in total

1.  Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index.

Authors:  J L Haybittle; F G Hayhoe; M J Easterling; A M Jelliffe; M H Bennett; G Vaughan Hudson; B Vaughan Hudson; K A MacLennan
Journal:  Lancet       Date:  1985-04-27       Impact factor: 79.321

2.  Hodgkin and Sternberg-Reed cells contain antigens specific to late cells of granulopoiesis.

Authors:  H Stein; B Uchánska-Ziegler; J Gerdes; A Ziegler; P Wernet
Journal:  Int J Cancer       Date:  1982-03-15       Impact factor: 7.396

3.  Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's disease.

Authors:  S M Hsu; E S Jaffe
Journal:  Am J Clin Pathol       Date:  1984-07       Impact factor: 2.493

Review 4.  Immunohistological analysis of human lymphoma: correlation of histological and immunological categories.

Authors:  H Stein; K Lennert; A C Feller; D Y Mason
Journal:  Adv Cancer Res       Date:  1984       Impact factor: 6.242

5.  The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22).

Authors:  M H Bennett; K A MacLennan; M J Easterling; B Vaughan Hudson; A M Jelliffe; G Vaughan Hudson
Journal:  Clin Radiol       Date:  1983-09       Impact factor: 2.350

6.  Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms.

Authors:  G Delsol; K C Gatter; H Stein; W N Erber; K A Pulford; K Zinne; D Y Mason
Journal:  Lancet       Date:  1984-11-17       Impact factor: 79.321

7.  Hodgkin's disease, lymphocyte predominance type, nodular--a distinct entity? Unique staining profile for L&H variants of Reed-Sternberg cells defined by monoclonal antibodies to leukocyte common antigen, granulocyte-specific antigen, and B-cell-specific antigen.

Authors:  G S Pinkus; J W Said
Journal:  Am J Pathol       Date:  1985-01       Impact factor: 4.307

  7 in total
  5 in total

1.  Immunohistochemistry in lymphoma diagnosis.

Authors:  P A Hall
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-13

2.  Comparative quality assessment in immunocytochemistry: pilot study of CD15 staining in paraffin wax embedded tissue in Hodgkin's disease.

Authors:  C A Angel; A Warford; S J Day; I Lauder
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

3.  Distinction between cells in serous effusions using a panel of antibodies.

Authors:  A F Lauritzen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 4.  Value of CD15 immunostaining in diagnosing Hodgkin's disease: a review of published literature.

Authors:  P A Hall; A J D'Ardenne
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

5.  The Scotland and Newcastle epidemiological study of Hodgkin's disease: impact of histopathological review and EBV status on incidence estimates.

Authors:  R F Jarrett; A S Krajewski; B Angus; J Freeland; P R Taylor; G M Taylor; F E Alexander
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.